Clicky

Passage Bio, Inc.(PASG)

Description: Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.


Keywords: Medicine Organ Systems Rare Diseases Central Nervous System Disorders Nervous System Disorders Medicine Products Lipid Storage Disorders Monogenic Gm1 Rare Tadataka Yamada

Home Page: www.passagebio.com

PASG Technical Analysis

One Commerce Square
Philadelphia, PA 19103
United States
Phone: 267 866 0311


Officers

Name Title
Dr. William Chou M.D. CEO & Director
Dr. James M. Wilson M.D., Ph.D. Co-Founder & Chief Scientific Advisor
Ms. Simona King CFO & Corp. Sec.
Mr. Alexandros Fotopoulos MBA, MSc Chief Technical Officer
Mr. Stuart M. Henderson VP of Corp. Devel. & Investor Relations
Mr. Edgar B. Cale Esq., J.D. Gen. Counsel & Company Sec.
Gregory Fuest VP of Global Commercial Strategy & Marketing
Dr. Mark Forman M.D., Ph.D. Chief Medical Officer
Desiree Luthman D.D.S. Sr. VP of Global Regulatory Affairs
David Weinstein M.D. Sr. VP of Clinical Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3039
Price-to-Sales TTM: 0
IPO Date: 2020-02-28
Fiscal Year End: December
Full Time Employees: 133
Back to stocks